ArticleISRN dermatology2011
Nevus senescence.
Article in ISRN dermatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Downregulation of Cyclin Kinase Inhibitors p16INK4a and p27 in Conjunctival Melanomas.Investigative ophthalmology & visual science · 2026Article
- Validity of Xiphophorus fish as models for human disease.Disease models & mechanisms · 2024Review
- The long-term evolution of melanocytic nevi among high-risk adults.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Article
- The WHO 2018 Classification of Cutaneous Melanocytic Neoplasms: Suggestions From Routine Practice.Frontiers in oncology · 2021Review
- A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma.Cancers · 2019Review
- Comparison of telomere length and insulin-like growth factor-binding protein 7 promoter methylation between breast cancer tissues and adjacent normal tissues in Turkish women.Journal of clinical laboratory analysis · 2017Article
- UV radiation promotes melanoma dissemination mediated by the sequential reaction axis of cathepsins-TGF-β1-FAP-α.British journal of cancer · 2017Article
- Senescence-Like Phenotypes in Human Nevi.Methods in molecular biology (Clifton, N.J.) · 2017Article
- A murine model for the development of melanocytic nevi and their progression to melanoma.Molecular carcinogenesis · 2016Article
- Recurrence of Dysplastic Nevi Is Strongly Associated with Extension of the Lesions to the Lateral Margins and into the Deep Margins through the Hair Follicles in the Original Shave Removal Specimens.Dermatology research and practice · 2016Article
- Growth-Curve Modeling of Nevi With a Peripheral Globular Pattern.JAMA dermatology · 2015Article
- Conceptual approach to early melanoma detection: models, tools, issues and challenges.Melanoma management · 2015Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanomas and nevi share many of the same growth-promoting mutations. However, melanomas grow relentlessly while benign nevi eventually undergo growth arrest and stabilize. The difference in their long-term growth potential may be attributed to activation of cellular senescence pathways. The primary mediator of senescence in nevi appears to be p16. Redundant, secondary senescence systems are also present and include the p14-p53-p21 pathway, the IGFBP7 pathway, the FBXO31 pathway, and the PI3K mediated stress induced endoplasmic reticulum unfolded protein response. It is evident that these senescence pathways result in an irreversible arrest in most instances; however, they can clearly be overcome in melanoma. Circumvention of these pathways is most frequently associated with gene deletion or transcriptional repression. Reactivation of senescence mechanisms could serve to inhibit melanoma tumor progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.